The Clever Chek TD-3250 Blood Glucose and Blood Pressure Measurement System is intended for in vitro diagnostic use. The system is intended to be used for the quantitative measurement of capillary whole blood from the fingertip. It is intended for use by healthcare professionals and people with diabetes mellitus at home as an aid in monitoring the effectiveness of a diabetes control program. It is not intended for the diagnosis of or screening for diabetes mellitus, and is not intended for use on neonates.

The system is also intended to be used to measure non-invasively the systolic and diastolic blood pressure and pluse rate of an adult individual, over age 16, at home by using a technique in which an inflatable cuff is wrapped around the arm. The cuff circumference is limited to 9.4 inches to ~ 13.8 inches.

Device Description

The CLEVER CHEK TD-3250™ blood glucose and blood pressure measurement system consists of a meter with arm cuff and test strips. The system utilizes an electrochemical method-based meter and dry reagent biosensor (test strips) for blood glucose testing. The size of the current is proportional to the amount of glucose present in the sample, providing a quantitative measurement of glucose in fresh whole blood and control solutions. Also, the system adopts the "oscillometric method" to as the measuring principle and provides the measurement of the systolic and diastolic blood pressure and heart rate of an individual by using a non-invasive technique in which as inflatable cuff is wrapped around the . The pressure sensor converts tiny alterations in arm cuff pressure to electrical signals, by analyzing those signals to determine the systolic and diastolic blood pressure and calculating pulse rate.

AI/ML Overview

The provided 510(k) summary for the CLEVER CHEK TD-3250™ system describes performance studies in general terms ("The performance of the CLEVER CHEK TD-3250™ system was studied in the laboratory and in clinical settings by healthcare professionals and lay users. The studies demonstrated that the CLEVER CHEK TD-3250™ system is suitable for its intended use."). However, it does not explicitly state specific acceptance criteria or provide detailed quantitative results from studies that prove the device meets these criteria.

Therefore, I cannot populate all sections of your request with specific details. Based on the information available, here's what can be extracted and what remains unknown:

1. Table of Acceptance Criteria and Reported Device Performance

Acceptance Criteria	Reported Device Performance
Blood Glucose Measurement	The document states "The studies demonstrated that the CLEVER CHEK TD-3250™ system is suitable for its intended use." This is a qualitative statement, not a quantitative performance metric against specific acceptance criteria.
Blood Pressure Measurement	The document states "The studies demonstrated that the CLEVER CHEK TD-3250™ system is suitable for its intended use." This is a qualitative statement, not a quantitative performance metric against specific acceptance criteria.
(Specific glucose accuracy standards, e.g., ISO 15197, are not mentioned. Specific blood pressure accuracy standards are also not mentioned.)	(No specific accuracy, precision, or other performance statistics are provided for either blood glucose or blood pressure.)

2. Sample Sizes Used for the Test Set and Data Provenance

Test Set Sample Size: Not specified.
Data Provenance: Studies were conducted "in the laboratory and in clinical settings by healthcare professionals and lay users." The country of origin is not explicitly stated for these studies, but the manufacturer is based in Taiwan.

3. Number of Experts Used to Establish Ground Truth for the Test Set and Their Qualifications

Number of Experts: Not specified.
Qualifications of Experts: Not specified.

4. Adjudication Method for the Test Set

Adjudication Method: Not specified.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done

MRMC Study: No, there is no mention of a multi-reader multi-case (MRMC) comparative effectiveness study, nor any effect size information regarding human readers with or without AI assistance. The device is a diagnostic system, not an AI-assisted diagnostic aid for human readers.

6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done

Standalone Study: Yes, the performance studies implicitly refer to the standalone performance of the device ("The performance of the CLEVER CHEK TD-3250™ system was studied..."). However, no specific details or results from these standalone tests are provided beyond a general statement of suitability.

7. The Type of Ground Truth Used

Ground Truth Type: Not specified. For blood glucose, ground truth typically involves a laboratory reference method. For blood pressure, it typically involves a validated reference sphygmomanometer reading. These methods are not explicitly stated.

8. The Sample Size for the Training Set

Training Set Sample Size: Not applicable. This device is described as utilizing an electrochemical method and an oscillometric method. There is no indication that it is an AI/machine learning-based device that would require a "training set" in the conventional sense.

9. How the Ground Truth for the Training Set Was Established

Ground Truth for Training Set: Not applicable (as above).

Summary of what is known:

Device Type: Blood Glucose and Blood Pressure Measurement System.
Measurement Methods: Electrochemical for glucose, oscillometric for blood pressure.
Studies Conducted: "Laboratory and clinical settings by healthcare professionals and lay users."
Overall Conclusion: "The CLEVER CHEK TD-3250™ system demonstrates satisfactory performance and is suitable for their intended uses."

Summary of what is NOT known from the provided text:

Specific quantitative acceptance criteria for either blood glucose or blood pressure.
Specific quantitative performance results (e.g., accuracy, precision, bias).
Sample sizes for any of the studies.
Details about the experts or ground truth establishment methods.
Any information regarding AI/machine learning training sets or human-in-the-loop studies.

To get the specific details requested in your prompt, one would need to refer to the full 510(k) submission document, which often contains detailed study protocols and results in appendices. The provided "510(k) Summary" is, by nature, a high-level overview.

Summary

{0}------------------------------------------------

K061073

Page 1-of-3

JUN - 2 2006

510 (k) Summary

Submitter Information Manufacturer Contact person

Address

Phone FAX E-mail Date Prepared

Name of Device Trade Names

Common Names/Descriptions

Classification Names

Predicate Device Trade/Proprietary Name:

Common/Usual Name:

Manufacturer

510 (k) Number

TaiDoc Technology Corporation Shu-Mei Wu 4F, No. 88, Sec. 1, Kwang-Fu Rd., San-Chung, Taipei County, Taiwan +886-2-66358080 +886-2-66355959 shumei@taidoc.com.tw April 14, 2006

CLEVER CHEK TD-3250TM

Blood Glucose and Blood Pressure Measurement System Blood Glucose and Blood Pressure Measurement System Blood Glucose Test Strips Class II devices 21 CFR Section 862.1345, Glucose Test System; 21 CFR Section 870.1130, Non-invasive Blood Pressure Measurement System

Achtung TD-4207 Blood Glucose Test System BpTRU Automated Non-Invasive Blood Pressure Monitoring, BMP-100 Blood Glucose Meter; Non-invasive Blood Pressure Measurement System Blood Glucose Test Strips TaiDoc Technology Corporation. VSM MedTech Ltd. K042005; K012636

iii

{1}------------------------------------------------

Page 2-of-3

4. Device Description

5. Intended Uses

The CLEVER CHEK TD-3250™ system is indicated for the quantitative measurement of glucose in fresh whole blood (capillary blood) for self testing by persons with diabetes in the home or by healthcare professionals in healthcare facilities. Testing is done outside the body (in vitro diagnostic use). The system also intended to use non-invasive measure the systolic and diastolic blood pressure and pulse rate or an adult individual, over age 16, at home by using a non-invasive technique in which an inflatable cuff is wrapped around the . The arm cuff circumference is limited to 9.4"~13.8".

6. Comparison to Predicate Device

The CLEVER CHEK TD-3250™ system has equivalent technological characteristics as the Achtung TD-4207 Blood Glucose Test System (K042005) and BpTRU Automated Non-invasive Blood Pressure Monitor, BP-100 (K012636). The CLEVER CHEK TD-3250™ system also has the same intended use as the Achtung TD-4207 Blood Glucose Test System and BpTRU Automated Non-invasive Blood Pressure Monitor, BP-100.

7. Performance Studies

The performance of the CLEVER CHEK TD-3250™ system was studied in the laboratory and in clinical settings by healthcare professionals and lay users. The studies demonstrated that the CLEVER CHEK TD-3250™ system is suitable for its intended use

{2}------------------------------------------------

Page 3-of-3

Conclusions

The CLEVER CHEK TD-3250™ system demonstrates satisfactory performance and is suitable for their intended uses.

:

and the comments of the comments of

and the contraction of the comments of the count

{3}------------------------------------------------

Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized depiction of an eagle or bird-like figure with three curved lines representing its body and wings. The logo is surrounded by a circular border containing the text "DEPARTMENT OF HEALTH & HUMAN SERVICES. USA".

Food and Drug Administration 2098 Gaither Road Rockville MD 20850

JUL 2 5 2006

Shu-Mei Wu, Ph.D. Project Manager Taidoc Technology Corporation 4F, 88, Sec.1, Kwang Fu Road San Chung, Taipei China (Taiwan) 241

K061073 Re: Trade/Device Name: Clever Chek TD-3250 Blood Glucose and Blood Pressure Measurement System Regulation Number: 21 CFR 862.1345 Regulation Name: Glucose test system Regulatory Class: Class II Product Code: NBW, CGA, JJX, DXN Dated: April 14, 2006 Received: April 17, 2006

Dear Dr. Shu-Mei Wu:

This letter corrects our substantially equivalent letter of June 2, 2006.

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

{4}------------------------------------------------

Page 2 - Dr. Shu-Mei Wu

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240)276-0484. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html

Sincerely yours,

Carol Benson for

Alberto Gutierrez Director Division of Chemistry and Toxicology Office of In Vitro Diagnostics Device Evaluation and Safety Center for Devices and Radiological Health

{5}------------------------------------------------

Indications for Use

510(k) Number (if known): K061073

Device Name: Clever Chek TD-3250 Blood Glucose and Blood Pressure Measurement System

Indications For Use:

Prescription Use (Part 21 CFR 801 Subpart D)

Image /page/5/Picture/7 description: The image shows the text "AND/OR" with a circle around it. The text is written in all capital letters. The circle is drawn around the entire text.

Over-The-Counter Use (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

Carol C. Benson
Division Sign-Off

Division Sign-Off

Office of In Vitro Diagnostic Device Evaluation and Safety

Page 1 of

510(k) K061073

Regulation Number and Section

§ 870.1130 Noninvasive blood pressure measurement system.

(a)
Identification. A noninvasive blood pressure measurement system is a device that provides a signal from which systolic, diastolic, mean, or any combination of the three pressures can be derived through the use of tranducers placed on the surface of the body.(b)
Classification. Class II (performance standards).